Kirkland Advises Altaris on Acquisition of Minaris Regenerative Medicine
September 26, 2024
September 26, 2024
CHICAGO, Illinois, Sept. 26 -- Kirkland and Ellis, a law firm, issued the following news release:
Kirkland & Ellis advised investment firm Altaris, LLC on the pending acquisition of Minaris Regenerative Medicine from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004). Minaris is a cell therapy contract development and manufacturing organization that provides autologous and allogeneic manufacturing services for pharmaceutical and biotech customers globa . . .
Kirkland & Ellis advised investment firm Altaris, LLC on the pending acquisition of Minaris Regenerative Medicine from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004). Minaris is a cell therapy contract development and manufacturing organization that provides autologous and allogeneic manufacturing services for pharmaceutical and biotech customers globa . . .